(Q44176443)

English

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection

scientific article published on 17 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection (English)

1 reference

Europe PubMed Central

30 November 2017

1 reference

based on heuristic

inferred from title

Marit J. van Gils

2

1 reference

Europe PubMed Central

30 November 2017

Evelien M. Bunnik

object named as

Evelien M Bunnik

1

0 references

Hanneke Schuitemaker

6

object named as

Hanneke Schuitemaker

1 reference

Europe PubMed Central

30 November 2017

author name string

Marilie S D Lobbrecht

3

1 reference

Europe PubMed Central

30 November 2017

Linaida Pisas

4

1 reference

Europe PubMed Central

30 November 2017

Ad C van Nuenen

5

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

17 June 2009

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

390

1 reference

Europe PubMed Central

30 November 2017

2

1 reference

Europe PubMed Central

30 November 2017

348-355

1 reference

Europe PubMed Central

30 November 2017

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV p24gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Isolation and propagation of HIV-1 on peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

Rapid and simple method for purification of nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.05.028

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2009.05.028

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44176443&oldid=2108293275"